Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06112340 · ClinicalTrials.gov registry record · Phase 2
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
A Phase 2 study of Eye Diseases and Thyroid Eye Disease, sponsored by Sling Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 2
- Study locations
NCT06112340 is a Phase 2 study of Eye Diseases and Thyroid Eye Disease that is actively recruiting participants, run by Sling Therapeutics. The registered enrollment target is 75 participants, below the 741,300-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06112340, a Phase 2 study of Eye Diseases and Thyroid Eye Disease, is actively recruiting participants, sponsored by Sling Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 2
- Study locations
Study Summary
The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during the Follow-Up Period of VGN-TED-301.
Conditions Studied
Interventions
- DRUG linsitinib
Study Locations (2)
Florida
- Bascom Palmer Eye Institute - Miami
West Virginia
- West Virginia University Eye Institute - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2023-10-11 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06112340
The ClinicalTrials.gov registry entry for NCT06112340 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 741,300-participant average among 27 other Eye Diseases trials with a reported enrollment target (100% lower). The listed sponsor is Sling Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Eye Diseases appearing as the primary indexed condition, and to 1 intervention - of which linsitinib is the first listed.
NCT06112340 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, West Virginia.
Frequently Asked Questions
What is clinical trial NCT06112340 about?
NCT06112340 is a clinical study titled "Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)". The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled in the prior VGN-TED-301 through Week 24. These subjects include VGN-TED-301 Week 24 proptosis non-responders or subjects who relapse during t...
What is the current status of trial NCT06112340?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2023-10-11. Estimated completion is 2026-06.
What conditions does trial NCT06112340 study?
This clinical trial studies the following conditions: Eye Diseases, Thyroid Eye Disease, Endocrine System Diseases, Graves Ophthalmopathy, Thyroid Diseases.
What interventions are being tested in trial NCT06112340?
The interventions under investigation include: linsitinib (DRUG).
Who is sponsoring clinical trial NCT06112340?
This trial is sponsored by Sling Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06112340 being conducted?
This trial has 2 study locations across Florida, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eye Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]
COMPLETED · Phase 2
-
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
COMPLETED · Phase 2
-
Anecortave Acetate for Treatment of Steroid Induced Intraocular Pressure (IOP) Elevation
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.